Quest Diagnostics price target raised to $185 from $175 at Barclays

Barclays raised the firm’s price target on Quest Diagnostics (DGX) to $185 from $175 and keeps an Equal Weight rating on the shares. The company’s “strong” Q1 reinforces Quest “as a relatively safe place to hide,” the analyst tells investors in a research note. The firm views the reiterated guidance as “achievable-to-beatable.”